Sewankambo, Nelson2022-02-152022-02-152008Kiwanuka, N., Laeyendecker, O., Robb, M., Kigozi, G., Arroyo, M., McCutchan, F., ... & Gray, R. (2008). Effect of human immunodeficiency virus Type 1 (HIV-1) subtype on disease progression in persons from Rakai, Uganda, with incident HIV-1 infection. The Journal of infectious diseases, 197(5), 707-13.https://doi.org/10.1086/527416https://nru.uncst.go.ug/xmlui/handle/123456789/2138Background. Human immunodeficiency virus type 1 (HIV-1) subtypes differ in biological characteristics that may affect pathogenicity. Methods. We determined the HIV-1 subtype—specific rates of disease progression among 350 HIV-1 seroconverters. Subtype, viral load, and CD4+ cell count were determined. Cox proportional hazards regression modeling was used to estimate adjusted hazard ratios (HRs) of progression to acquired immunodeficiency syndrome (AIDS) (defined as a CD4+ cell count of ⩽250 cells/mm3) and to AIDS-associated death. Results. A total of 59.1% of study subjects had subtype D strains, 15.1% had subtype A, 21.1% had intersubtype recombinant subtypes, 4.3% had multiple subtypes, and 0.3% had subtype C. Of the 350 subjects, 129 (37%) progressed to AIDS, and 68 (19.5%) died of AIDS. The median time to AIDS onset was shorter for persons with subtype D(6.5 years), recombinant subtypes (5.6 years), or multiple subtypes (5.8 years), compared with persons with subtype A (8.0 years; P = .022). Relative to subtype A, adjusted HRs of progression to AIDS were 2.13 [95% confidence interval {CI}, 1.10–4.11] for subtype D, 2.16 [95% CI, 1.05–4.45] for recombinant subtypes, and 4.40 [95% CI, 1.71–11.3] for multiple subtypes. The risk of progression to death was significantly higher for subtype D(adjusted HR, 5.65; 95% CI, 1.37–23.4), recombinant subtypes (adjusted HR, 6.70; 95% CI, 1.56–28.8), and multiple subtypes (adjusted HR, 7.67; 95% CI, 1.27–46.3), compared with subtype A. Conclusions. HIV disease progression is affected by HIV-1 subtype. This finding may impact decisions on when to initiate antiretroviral therapy and may have implications for future trials of HIV-1 vaccines aimed at slowing disease progression.enHuman Immunodeficiency Virus Type 1Disease ProgressionRakaiUgandaArticle